Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBK351)

• DTT Name: Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)
• Synonyms: Terminal protein; Latent membrane protein 2
• Gene Name: EBV LMP2
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Herpesviridae LMP-2
• UniProt ID: LMP2_EBVB9
• TTD ID: T33636
• Sequence:
  MGSLEMVPMGAGPPSPGGDPDGYDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPPY
  EDPYWGNGDRHSDYQPLGTQDQSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGSM
  NPVCLPVIVAPYLFWLAAIAASCFTASVSTVVTATGLALSLLLLAAVASSYAAAQRKLLT
  PVTVLTAVVTFFAICLTWRIEDPPFNSLLFALLAAAGGLQGIYVLVMLVLLILAYRRRWR
  RLTVCGGIMFLACVLVLIVDAVLQLSPLLGAVTVVSMTLLLLAFVLWLSSPGGLGTLGAA
  LLTLAAALALLASLILGTLNLTTMFLLMLLWTLVVLLICSSCSSCPLSKILLARLFLYAL
  ALLLLASALIAGGSILQTNFKSLSSTEFIPNLFCMLLLIVAGILFILAILTEWGSGNRTY
  GPVFMCLGGLLTMVAGAVWLTVMSNTLLSAWILTAGFLIFLIGFALFGVIRCCRYCCYYC
  LTLESEERPPTPYRNTV
• Function: Isoform LMP2B may be a negative regulator of isoform LMP2A.

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMP-1/LMP-2 CTLs	DMZU2G1	Lymphoma	2A80-2A86	Phase 1	[1]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad5f35-LMPd1-2-transduced autologous dendritic cells	DMQW612	Nasopharyngeal carcinoma	2B6B	Investigative	[2]

References

• [1] In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
• [2] CA patent application no. 876139, Nanotherapeutics for drug targeting.